Bevurogant(Bevurogant) - 药物靶点：RORγt_在研适应症：自身免疫性疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

RORγt

作用机制

RORγt抑制剂(视黄酸相关孤儿受体γt抑制剂)

治疗领域

免疫系统疾病

在研适应症

自身免疫性疾病

非在研适应症

银屑病关节炎斑块状银屑病

原研机构

Boehringer Ingelheim GmbH

在研机构

Boehringer Ingelheim Pharmaceuticals, Inc.

非在研机构

Boehringer Ingelheim GmbHBoehringer Ingelheim Pharma GmbH & Co., KGBoehringer Ingelheim International GmbH

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)终止

特殊审评-

登录后查看时间轴

结构

分子式C26H28N8O3S

InChIKeyHVVHIBHBDCYLDI-HNNXBMFYSA-N

CAS号1817773-66-2

关联

17

项与 Bevurogant 相关的临床试验

NCT04680676 / Withdrawn临床2期

A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging, Proof-of-concept Trial of BI 730357 Given for 12 Weeks in Patients With Active Psoriatic Arthritis

This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to joints.
Three different doses of BI 730357 are tested. Participants are put into 4 groups by chance. Participants in 3 of the 4 groups take BI 730357. Participants in the fourth group take placebo. Participants take BI 730357 or placebo as tablets once a day. Placebo tablets look like BI 730357 tablets but do not contain any medicine.
Participants are in the study for about 4.5 months. During this time, they visit the study site about 8 times. At these visits, doctors check whether the swelling of inflamed joints has changed. The results between the BI 730357 and placebo groups are then compared. Doctors also regularly check the general health of the participants.

开始日期2022-05-02

申办/合作机构

Boehringer Ingelheim GmbH

ACTRN12620001092987 / Not yet recruiting临床2期

A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, efficacy and safety trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis

开始日期2022-04-04

申办/合作机构

Boehringer Ingelheim Pty Ltd.

NCT04679948 / Completed临床1期

The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)

The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.

开始日期2020-12-21

申办/合作机构

Boehringer Ingelheim GmbH

100 项与 Bevurogant 相关的临床结果

登录后查看更多信息

100 项与 Bevurogant 相关的转化医学

登录后查看更多信息

100 项与 Bevurogant 相关的专利（医药）

登录后查看更多信息

4

项与 Bevurogant 相关的文献（医药）

2024-02-01·Clinical Pharmacology in Drug Development

The Effect of BI 730357 (Retinoic Acid‐Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open‐Label, Non‐randomized, 2‐Period Fixed‐Sequence Trial in Healthy Subjects

Article

作者: Flack, Mary ; Huang, Fenglei ; Choi, HeeJae

AbstractEvaluating Drug‐Drug Interactions (DDIs) for new investigational compounds requires several trials evaluating different drugs with different transporter specificities. By using a cocktail of drugs with different transporter specificities, a single trial could evaluate the pharmacokinetics (PKs) of each cocktail drug simultaneously, reducing the number of clinical DDI trials required for clinical development. We aimed to investigate the effect of steady‐state Boehringer Ingelheim (BI) 730357 (bevurogant) on the PKs of a validated and optimized 4‐component transporter cocktail. This open‐label, non‐randomized, 2‐period fixed‐sequence phase I trial compared transporter cocktail (0.25 mg digoxin/1 mg furosemide/10 mg metformin hydrochloride/10 mg rosuvastatin) with and without BI 730357 in healthy subjects aged 18‐55 years with body mass index 18.5‐29.9 kg/m2. During reference treatment/period 1, transporter cocktail was administered 90 minutes after breakfast. After a washout period, during test treatment/period 2, BI 730357 was dosed twice daily for 13 days, with transporter cocktail administered on day 1. The primary endpoints were the area under the concentration‐time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0‐∞) and the maximum measured concentration of the analyte in plasma (Cmax), and the secondary endpoint was the area under the concentration‐time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0‐tz). Steady‐state BI 730357 increased digoxin (+48% to +94%), minimally affected metformin (−2% to −9%), furosemide (+12% to +18%), and rosuvastatin (+19% to +39%) exposure. Therefore, no clinically relevant inhibition of transporters OCT2/MATE‐1/MATE‐2K, OAT1/OAT3, OATP1B1/OATP1B3 was observed. Potential inhibition of breast cancer resistance protein noted as PK parameters of coproporphyrin I/III (OATP1B1/OATP1B3 biomarkers) remained within bioequivalence boundaries while rosuvastatin PK parameters (AUC0‐∞/Cmax/AUC0‐tz) exceeded the bioequivalence boundary. BI 730357 was safe and well tolerated. This trial confirms the usefulness and tolerability of the transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin in assessing drug‐transporter interactions in vivo.

2023-06-01·CPT: pharmacometrics & systems pharmacology

Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357.

Article

作者: Kristoffersson, Anders ; Ooi, Qing Xi ; Flack, Mary ; Weber, Benjamin ; Korell, Julia ; Plan, Elodie

BI 730357 is investigated as an oral treatment of plaque psoriasis. We analyzed the impact of three dosage regimens on the Psoriasis Area and Severity Index (PASI) response with modeling based on phase I and II data from 109 healthy subjects and 274 patients with moderate-to-severe plaque psoriasis. The pharmacokinetics (PK) was characterized by a two-compartment model with dual absorption paths and a first-order elimination. Higher baseline C-reactive protein was associated with lower clearance and patients generally had lower clearance compared with healthy subjects. A bounded integer PK/pharmacodynamic model characterized the effect on the observed PASI. The maximum drug effect was largest for patients with no prior biologic use, smaller for patients with prior use of non-interleukin-17 inhibitors, and smallest for patients with prior interleukin-17 inhibitor use. The models allowed robust simulation of large patient populations, predicting a plateau in PASI outcomes for BI 730357 exposure above 2000 nmol/L.

2021-12-02·Expert Opinion on Drug Discovery3区 · 医学

Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?

3区 · 医学

Review

作者: Gege, Christian

Introduction: The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of T_H17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Several orally or topically administered small molecule RORγt inverse agonists (RIAs) have progressed up to the end of clinical Phase 2.Areas covered: Based on publications and patent evaluations this review summarizes the evolution of the chemical matter for all 16 pharmaceutical companies, who develop(ed) a clinical-stage RIAs (until March 2021). Structure proposals for some clinical stage RIAs are presented and the outcome of the clinical trials is discussed.Expert opinion: So far, the clinical trials have been plagued with a high attrition rate. Main reasons were lack of efficacy (topical) or safety signals (oral) as well as, amongst other things, thymic lymphomas as seen with BMS-986251 in a preclinical study and liver enzyme elevations in humans with VTP-43742. Possibilities to mitigate these risks could be the use of RIAs with different chemical structures not interfering with thymocytes maturation and no livertox-inducing properties. With new frontrunners (e.g., ABBV-157 (cedirogant), BI 730357 or IMU-935) this is still an exciting time for this treatment approach.

1

项与 Bevurogant 相关的新闻（医药）

2021-06-18

·GlobeNewswire

Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others. DelveInsight’s ‘Axial Spondyloarthritis (axSpA) Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the important takeaways from the Axial Spondyloarthritis Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Axial Spondyloarthritis Emerging Therapies and Forecast The Axial Spondyloarthritis Pipeline reports lay down a thorough coverage of the ongoing clinical trials, collaborations taking place in the domain, recent happenings in the Axial Spondyloarthritis pipeline space, and growth prospects across the Axial Spondyloarthritis domain. Axial Spondyloarthritis: Overview Axial Spondyloarthritis is a chronic, inflammatory rheumatic disease that affects primarily the axial joints leading to severe pain, stiffness, and fatigue. It starts with an early inflammatory phase in which there is no structural damage in the sacroiliac joints (non-radiographic disease) progressing to later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis, or bony bridges (radiographic disease; also known as Ankylosing Spondylitis). Discover more about the disease, treatments, and pipeline therapies @ axSpA Pipeline Assessment Axial Spondyloarthritis Pipeline Drugs Request for Sample to know more @ Axial Spondyloarthritis Pipeline Analysis, Key Companies, and Futuristic Trends Axial Spondyloarthritis Therapeutics Assessment The Axial Spondyloarthritis Pipeline report presents a kaleidoscopic view of the axSpA emerging novel therapies segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit Axial Spondyloarthritis Pipeline: Emerging Novel Therapies Scope of the Axial Spondyloarthritis Pipeline Report Coverage: GlobalKey Players: Izana Bioscience, UCB, Sun Pharma Global, Akeso Biopharma, Kinevant Sciences, Jiangsu Hengrui Medicine Co., Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, Mycenax Biotech, Boehringer Ingelheim, and Qyuns Therapeutics among others.Key Axial Spondyloarthritis Pipeline Therapies: Namilumab , Bimekizumab, Tofacitinib, Tildrakizumab, AK-111, NDI 031232, Gimsilumab, QX002N, SHR-0302, Jaktinib, SCB-808, FPP003, KIN-1901, ENIA11, BI 730357, and QX002N among others. Discover more about the report offerings @ axSpA Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions Related Reports Axial Spondyloarthritis MarketDelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030" report. Non-Radiographic Axial Spondyloarthritis MarketDelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2030" report. Spondylolisthesis Market InsightsDelveInsight's “Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2030" report. Ankylosing Spondylitis MarketDelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2030’ report. Global Kinase Inhibitor In Autoimmune Diseases MarketDelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report. Adenosine Deaminase Severe Combined Immunodeficiency MarketDelveInsight's "Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2030" report. Adult-Onset Still Disease MarketDelveInsight’s “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report. Browse through our posts ABSSSI Pipeline Analysis Parkinson's Disease Risk FactorsWearable Healthcare Devices Market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

合作

100 项与 Bevurogant 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	临床2期	-	Boehringer Ingelheim GmbH	2022-05-02
斑块状银屑病	临床2期	德国	Boehringer Ingelheim GmbH	2018-09-17
斑块状银屑病	临床2期	美国	Boehringer Ingelheim GmbH	2018-09-17
斑块状银屑病	临床2期	加拿大	Boehringer Ingelheim GmbH	2018-09-17
自身免疫性疾病	临床前	美国	Boehringer Ingelheim Pharmaceuticals, Inc.	2021-01-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03804671 (CTgov)	临床1期	-	6	[C-14] BI 730357	餘顧憲膚鬱淵鹽觸範艱(衊構遞觸製艱蓋顧鏇製) = 構網淵簾鹽夢選鏇鹽廠壓醖齋淵獵築廠獵構鬱 (衊觸窪鑰鏇廠蓋網壓構, 糧繭衊膚蓋衊製積鬱夢 ~ 夢廠鏇蓋範憲艱網鹹製) 更多	-	2023-07-25
NCT04147260 (CTgov)	临床1期	-	85	Placebo (Placebo QD)	夢鹽襯鹽繭獵獵積廠壓(餘積鹽顧鏇憲鹹夢製夢) = 醖糧襯築夢鏇衊襯憲願糧獵積觸窪築夢艱願糧 (積夢鏇築鏇齋壓觸衊衊, 觸範構衊築製壓獵衊製 ~ 遞遞廠鹹積構鏇願衊繭) 更多	-	2023-07-17
				BI 730357 (400 mg QD BI 730357)	夢鹽襯鹽繭獵獵積廠壓(餘積鹽顧鏇憲鹹夢製夢) = 齋網繭鹹壓獵積憲築鑰糧獵積觸窪築夢艱願糧 (積夢鏇築鏇齋壓觸衊衊, 觸鬱廠鹽艱齋鏇遞選艱 ~ 鏇壓獵膚願願願獵廠鑰) 更多
NCT03886272 (CTgov)	临床1期	-	43	BI 730357 (50 mg BI 730357 iCF (T1))	蓋夢選積鬱繭壓壓構蓋(鬱繭糧憲鏇蓋鏇夢鹽壓) = 願選簾範選膚衊鹹鹹製糧壓壓範憲蓋製醖糧簾 (積艱憲齋鹹蓋觸選鹹獵, 廠範艱廠鏇艱夢簾廠廠 ~ 遞窪鏇鹽鏇齋獵夢築夢) 更多	-	2023-07-17
				TF1 (R1)+BI 730357 (50 mg BI 730357 TF1 (R1))	蓋夢選積鬱繭壓壓構蓋(鬱繭糧憲鏇蓋鏇夢鹽壓) = 膚廠網鏇憲鹽壓遞鏇糧糧壓壓範憲蓋製醖糧簾 (積艱憲齋鹹蓋觸選鹹獵, 鬱觸膚窪壓衊廠淵鹽願 ~ 鬱願艱獵醖窪襯齋齋壓) 更多
NCT03782987 (CTgov)	临床1期	-	14	itraconazole+BI 730357 (BI 730357 + Itraconazole (T))	鬱淵範襯繭鏇夢鹽簾憲(餘網餘憲鑰願憲鹽遞觸) = 廠壓蓋衊觸窪夢憲鬱鹽蓋築觸範顧鏇廠顧窪顧 (膚齋鑰簾顧淵積範廠願, 膚簾膚簾艱顧餘膚蓋獵 ~ 簾齋簾願繭鬱觸構繭壓) 更多	-	2023-07-12
				BI 730357 (BI 730357 (R))	鬱淵範襯繭鏇夢鹽簾憲(餘網餘憲鑰願憲鹽遞觸) = 簾憲鏇艱顧鑰積壓顧繭蓋築觸範顧鏇廠顧窪顧 (膚齋鑰簾顧淵積範廠願, 範齋淵鹽壓壓窪築鏇糧 ~ 選鹹蓋蓋淵顧積觸淵餘) 更多
NCT03664011 (CTgov)	临床1期	-	6	[C-14] BI 730357 base (BS)+BI 730357 BS (BI 730357)	襯艱鹽範艱獵鑰齋衊蓋(蓋醖糧鏇餘鏇襯範夢壓) = 艱鹹鬱餘顧繭觸簾憲廠壓構製衊淵鹽憲繭壓顧 (夢顧遞遞壓願願簾鑰遞, 夢壓鬱廠醖構選糧窪艱 ~ 廠窪壓鬱鹽衊鹹獵鬱築) 更多	-	2023-07-12
				BI 730357 (14C-BI 730357-EQ and BI 730357)	齋遞簾選遞製築繭廠憲(積選願壓選膚網獵鑰鑰) = 鏇膚鹹觸齋築鹽壓顧鹽壓鬱窪鑰膚選蓋淵艱鹽 (壓蓋簾範齋淵糧糧鬱製, 鹹艱艱構壓衊襯餘簾選 ~ 構築窪選鹹願壓範鬱憲) 更多
NCT03793621 (CTgov)	临床1期	-	24	Placebo	網遞簾醖繭觸淵繭窪觸(獵餘遞鏇齋齋觸壓淵淵) = 網鹹獵繭繭襯憲選衊鹹廠鬱鑰襯選選齋窪觸艱 (鏇襯壓製範網遞鹽襯蓋, 範鹹繭積構範範築網鬱 ~ 顧築襯艱範糧淵遞衊齋) 更多	-	2023-07-12